Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Polycystic Ovary Syndrome 9Hyperandrogenism 4Neoplasms 3Inflammation 2Heart Failure 2Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Skin Diseases 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Sarcoma 1Retinitis 1Renal Insufficiency, Chronic 1Rare Diseases 1Pulmonary Arterial Hypertension 1Pneumonia 1Pain 1Obesity 1Neutropenia 1Migraine Disorders 1Metabolic Syndrome 1Menorrhagia 1Meningitis, Bacterial 1Meningitis 1Lymphoma 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 562Azacitidine 386venetoclax 311Cyclophosphamide 289fludarabine 246fludarabine phosphate 229Decitabine 187Busulfan 176Daunorubicin 156Idarubicin 151Peripheral Blood Stem Cell Transplantation 138Mycophenolic Acid 134Filgrastim 134Whole-Body Irradiation 133Tacrolimus 125Granulocyte Colony-Stimulating Factor 124Etoposide 117Mitoxantrone 103Methotrexate 103Melphalan 103Cyclosporine 101Antilymphocyte Serum 85Gemtuzumab 84Clofarabine 84Specimen Handling 75Injections 69Stem Cell Transplantation 64Biopsy 59CPX-351 56Thiotepa 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × Spironolactone × Clear all
NCT03867682 2023-08-04

Venetoclax and Lintuzumab-Ac225 in AML Patients

Actinium Pharmaceuticals

Phase 1/2 Unknown
38 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡